Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.58 USD

1.58
1,271,998

+0.04 (2.60%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.58 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LXRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lexicon Pharmaceuticals, Inc. [LXRX]

Reports for Purchase

Showing records 361 - 380 ( 393 total )

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 361

08/16/2012

Daily Note

Pages: 8

Positive LX2931 and LX7101 Phase 1/2 Data Expands The Pipeline and Supports Future Business Development In Our View.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 362

08/15/2012

Industry Report

Pages: 24

Life Sciences MAC Best Ideas Conference - New York City - August 14 & 15, 2012 Day 1 Key Takeaways

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 363

08/10/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 364

08/10/2012

Industry Report

Pages: 7

Life Sciences MAC Best Ideas Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 365

08/06/2012

Industry Report

Pages: 17

August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 366

07/31/2012

Company Report

Pages: 10

Q2 Financials In-Line. Next Value-Drivers: Phase II LX2931 and LX7101 Data Releases in Q3. Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 367

07/27/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 368

07/20/2012

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 369

07/06/2012

Industry Report

Pages: 17

Emerging Pharmaceuticals - July and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 370

06/25/2012

Daily Note

Pages: 11

Positive LX4211 Phase 2b Data Sets Up Potential Partnership Announcement In Our View. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 371

06/22/2012

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of June 24

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 372

06/14/2012

Company Report

Pages: 14

LX4211 Stands Out At ADA; Next Value-Driver: Phase 2b Data Release in late June - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 373

06/14/2012

Company Report

Pages: 14

LX4211 Stands Out At ADA; Next Value-Driver: Phase 2b Data Release in late June - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 374

06/03/2012

Industry Report

Pages: 19

Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 375

05/25/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 27

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 376

05/18/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 377

05/16/2012

Industry Report

Pages: 25

Catalysts for May and Rest of 2012 for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 378

05/08/2012

Daily Note

Pages: 7

LX1033 Data To Be Presented at DDW Confirms Potency and Biomarker Utility

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 379

05/03/2012

Company Report

Pages: 10

Q1 Financials In Line; Next Value-Driver: Phase 2 LX4211 Data Release in late June; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 380

04/13/2012

Daily Note

Pages: 6

We Anticipate Phase 2b LX4211 Data Release At The End Of Q2 As The Next Major Value-Driver . Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party